Trial reportPloS one2013
Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS).
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000553. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HDL-Atherosclerosis Treatment Study (HATS)
Open the trial in the graphWho cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Pooled it
- Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.Nature communications · 2014Pooled it
- Combined effect of plant sterols and dietary fiber for the treatment of hypercholesterolemia.Plant foods for human nutrition (Dordrecht, Netherlands) · 2014Pooled it
- Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.Atherosclerosis · 2016 · on this mapTrial
- Trial
- Effect of a moderate fat diet with and without avocados on lipoprotein particle number, size and subclasses in overweight and obese adults: a randomized, controlled trial.Journal of the American Heart Association · 2015Trial
- Estimated small dense low-density lipoprotein-cholesterol and the risk of kidney and cardiovascular outcomes in diabetic kidney disease.Renal failure · 2024Article
- Sex-specific responses in glucose-insulin homeostasis and lipoprotein-lipid components after high-dose supplementation with marine n-3 PUFAs in abdominal obesity: a randomized double-blind crossover study.Frontiers in nutrition · 2023Article
- Small Dense LDL: Scientific Background, Clinical Relevance, and Recent Evidence Still a Risk Even with 'Normal' LDL-C Levels.Biomedicines · 2022Review
- Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases.Life (Basel, Switzerland) · 2021Review
- Small, Dense Low-Density Lipoprotein-Cholesterol and Atherosclerosis: Relationship and Therapeutic Strategies.Frontiers in cardiovascular medicine · 2021Review
- There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3-5.Scientific reports · 2020Article
- Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019Article
- Study on the levels of glycosylated lipoprotein in patients with coronary artery atherosclerosis.Journal of clinical laboratory analysis · 2019Article
- Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans.Chronic diseases and translational medicine · 2018Article
- Anti-atherosclerotic effect ofVeterinary research forum : an international quarterly journal · 2017Article
- Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.Lipids in health and disease · 2014Article
- Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease.The American journal of cardiology · 2014Article
- Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease.Atherosclerosis · 2014Article
- Approach to reduction of blood atherogenicity.Oxidative medicine and cellular longevity · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTest whether angiographically-documented changes in percent stenosis and clinical endpoints (coronary-related deaths, myocardial infarctions, stroke, revascularization for worsening ischemia) in the HDL-Atherosclerosis Treatment Study (HATS) were attributable to specific LDL-subclasses.
methodsGradient gel electrophoresis of on-study LDL-subclass cholesterol concentrations were measured in 32 placebo, 33 simvastatin-niacin, 38 antioxidant, and 39 simvastatin-niacin & antioxidant treated participants. The prespecified primary end point was the mean change per patient from the initial arteriogram to the final arteriogram in the percent stenosis caused by the most severe lesion in each of the nine proximal coronary segments.
resultsThe change in the percent stenosis of the most severe proximal lesions increased in association with higher concentrations of the small LDL subfractions LDL-IIIb (24.2-24.6 nm) and LDL-IVa (23.3-24.1 nm) before (both P = 0.002) and after (P = 0.01 and P = 0.03 respectively) adjustment for treatment group and on-study HDL-cholesterol, LDL-cholesterol, and triglyceride concentrations. The associations appeared specific to lesions with <30% baseline stenosis. When adjusted for age, sex, baseline BMI and cigarette use, the odds for primary clinical endpoints (death from coronary causes, nonfatal myocardial infarction, stroke, or revascularization for worsening ischemia) were significantly greater in subjects with higher on-study LDL-IIIb levels both before (P = 0.01) and after (P = 0.03) adjustment for treatment group and the standard lipid values.
conclusionsPlasma LDL-IIIb cholesterol concentrations were related to changes in coronary artery stenosis and cardiovascular events in patients with coronary artery disease and low HDL-cholesterol.
trial registrationClinicalTrials.gov NCT00000553.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.